Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer

Maryse Brassard; Barbara Neraud; Séverine Trabado; Sylvie Salenave; Sylvie Brailly-Tabard; Isabelle Borget; Eric Baudin; Sophie Leboulleux; Philippe Chanson; Martin Schlumberger; Jacques Young

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer

【24h】

Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer

机译：酪氨酸激酶抑制剂Vandetanib对甲状腺癌患者的内分泌作用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose:The purpose of the study was to assess the endocrine effects of vandetanib, a multikinase inhibitor targeting RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor, in 39 patients with progressive thyroid cancer included in two randomized placebo-controlled trials using vandetanib 300 mg/d.

机译：目的：该研究的目的是评估Vandetanib的内分泌作用，靶向RET，血管内皮生长因子受体和表皮生长因子受体，在39例随机安慰剂对照试验中包含的39例患者vandetanib 300 mg / d。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2011年第9期|共9页
作者
Maryse Brassard; Barbara Neraud; Séverine Trabado; Sylvie Salenave; Sylvie Brailly-Tabard; Isabelle Borget; Eric Baudin; Sophie Leboulleux; Philippe Chanson; Martin Schlumberger; Jacques Young;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. RESPONSE AND RESISTANCE TO THE RECEPTOR TYROSINE KINASE INHIBITOR (TKI) VANDETANIB IN PEDIATRIC PATIENTS WITH MEDULLARY THYROID CARCINOMA (MTC) [J] . Akshintala Srivandana, Dombi Eva, Glod John, Pediatric blood & cancer . 2015,第Suppla2期

机译：甲状腺髓样癌（MTC）患儿对酪氨酸激酶抑制剂（TKI）vandetanib的应答和耐药
2. Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR). [J] . Jin Soo Lee, Vera Hirsh, Keunchil Park, Journal of Clinical Oncology . 2012,第10期

机译：Vandetanib与安慰剂对先前接受过表皮生长因子受体酪氨酸激酶抑制剂的晚期非小细胞肺癌患者的治疗：一项随机双盲III期试验（ZEPHYR）。
3. Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? [J] . P. Mondello, M. Mian, V. Pitini, Current oncology . 2016,第3期

机译：甲状腺激素自身抗体：在接受酪氨酸激酶抑制剂或免疫调节药物治疗的血液系统癌症患者中，它们是否是检测早期甲状腺损害的更好标记？
4. MORPHOLOGICAL ANALYSIS OF COLON CANCER CELL TREATED WITH AEE788, A DUAL TYROSINE KINASE INHIBITOR AND/OR CELEXOXIB, A COX-2 SPECIFIC INHIBITOR- IMAGE PROCESSING APPROACH [C] . P Venkatesan, M Muthu Rama Krishnan, Soumen Das, International Conference on Electronic Design and Signal processing . 2012

机译：用AEE788处理的结肠癌细胞的形态学分析，双酪氨酸激酶抑制剂和/或Celexoxib，COX-2特异性抑制剂 - 图像处理方法
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Clinical Case Seminar: Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat—and With Which Drug—Those Are the Questions [O] . Maria E. Cabanillas, Mimi I. Hu, Camilo Jimenez -1

机译：临床案例研讨会：酪氨酸激酶抑制剂时代的髓样甲状腺癌：治疗还是不治疗以及用哪种药物治疗是问题
7. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors [O] . F. Illouz, D. Braun, C. Briet, 2014

机译：抗癌药物的内分泌副作用：酪氨酸激酶抑制剂的甲状腺作用

Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer

摘要

著录项

相似文献

相关主题

期刊订阅